Arcadia Investment Management Corp MI lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,065 shares of the medical instruments supplier’s stock after buying an additional 586 shares during the period. Becton, Dickinson and comprises 1.9% of Arcadia Investment Management Corp MI’s holdings, making the stock its 11th largest holding. Arcadia Investment Management Corp MI’s holdings in Becton, Dickinson and were worth $6,061,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. North Star Investment Management Corp. grew its holdings in Becton, Dickinson and by 3.4% during the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 18 shares during the last quarter. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and during the 1st quarter valued at about $105,000. Parkside Financial Bank & Trust grew its holdings in Becton, Dickinson and by 1.4% during the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 9 shares during the last quarter. QCI Asset Management Inc. NY grew its holdings in Becton, Dickinson and by 9.2% during the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 60 shares during the last quarter. Finally, Financial Architects Inc grew its holdings in Becton, Dickinson and by 8.0% during the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

Several equities analysts recently commented on BDX shares. BidaskClub downgraded shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a report on Tuesday. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $196.93.

WARNING: “Arcadia Investment Management Corp MI Boosts Stake in Becton, Dickinson and Company (BDX)” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/16/arcadia-investment-management-corp-mi-boosts-stake-in-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 195.34 on Friday. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63. The stock has a market capitalization of $44.45 billion, a PE ratio of 56.57 and a beta of 1.06. The firm has a 50-day moving average of $199.43 and a 200 day moving average of $191.33.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same period last year, the business earned $2.35 earnings per share. The business’s revenue for the quarter was down 5.1% on a year-over-year basis. Equities research analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.49%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the sale, the insider now owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 75,904 shares of company stock valued at $15,242,688. Company insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.